• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Myriad Genetics, Inc. - Common Stock (NQ: MYGN )

    13.50 -0.24 (-1.75%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 602,537
    Open 13.63
    Bid (Size) 13.43 (10)
    Ask (Size) 14.40 (1)
    Prev. Close 13.74
    Today's Range 13.44 - 13.65
    52wk Range 12.87 - 29.30
    Shares Outstanding 90,900,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
    Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model 
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
    From Myriad Genetics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -28.95%
    -28.95%
    1 Month
    -16.51%
    -16.51%
    3 Month
    -48.53%
    -48.53%
    6 Month
    -44.47%
    -44.47%
    1 Year
    -31.75%
    -31.75%

    More News

    Read More
    Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
    Via Benzinga
    Where Myriad Genetics Stands With Analysts
    Via Benzinga
    Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
    Via Benzinga
    NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Crude Oil Moves Higher; Apple Shares Slide After Q4 Results
    Via Benzinga
    Exposures Fossil Fuels
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results
    Via Benzinga
    Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.